Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 9, Issue 10, pp. 2825-2833
PubMed
Published By
Print ISSN
Online ISSN
History
- Received April 22, 2010
- Revision received July 24, 2010
- Accepted July 29, 2010
- Published first August 5, 2010.
Article Versions
- Previous version (August 5, 2010 - 08:02).
- Previous version (September 21, 2010 - 08:40).
- You are viewing the most recent version of this article.
Copyright & Usage
©2010 American Association for Cancer Research.
Author Information
- Isamu Okamoto1,
- Hiroyasu Kaneda1,2,
- Taroh Satoh1,
- Wataru Okamoto1,
- Masaki Miyazaki1,
- Ryotaro Morinaga1,
- Shinya Ueda1,
- Masaaki Terashima1,
- Asuka Tsuya1,
- Akiko Sarashina3,
- Koichi Konishi3,
- Tokuzo Arao2,
- Kazuto Nishio2,
- Rolf Kaiser4 and
- Kazuhiko Nakagawa1
- Authors' Affiliations: Departments of 1Medical Oncology and 2Genome Biology, Kinki University School of Medicine, Osaka-Sayama, Japan; 3Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan; and 4Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
- Corresponding Author:
Isamu Okamoto, Department of Medical Oncology, Kinki University School of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan. Phone: 81-72-366-0221; Fax: 81-72-360-5000. E-mail: chi-okamoto{at}dotd.med.kindai.ac.jp
October 2010
Volume 9, Issue 10
Volume 9, Issue 10
Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Jump to section
Advertisement